Stockreport

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF 5 min read In This Article PTN Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J. Feb. 6, 2025 /PRNewswire/ - [Read more]